HPV prevalence among women from Appalachia: results from the CARE project

Paul L Reiter, Mira L Katz, Mack T Ruffin, Erinn M Hade, Cecilia R DeGraffenreid, Divya A Patel, Electra D Paskett, Elizabeth R Unger, Paul L Reiter, Mira L Katz, Mack T Ruffin, Erinn M Hade, Cecilia R DeGraffenreid, Divya A Patel, Electra D Paskett, Elizabeth R Unger

Abstract

Background: Cervical cancer incidence and mortality rates are high among women from Appalachia, yet data do not exist on human papillomavirus (HPV) prevalence among these women. We examined the prevalence of genital HPV among Appalachian women and identified correlates of HPV detection.

Methods: We report data from a case-control study conducted between January 2006 and December 2008 as part of the Community Awareness, Resources, and Education (CARE) Project. We examined HPV prevalence among 1116 women (278 women with abnormal Pap tests at study entry [cases], 838 women with normal Pap tests [controls]) from Appalachian Ohio. Analyses used multivariable logistic regression to identify correlates of HPV detection.

Results: The prevalence of HPV was 43.1% for any HPV type, 33.5% for high-risk HPV types, 23.4% for low-risk HPV types, and 12.5% for vaccine-preventable HPV types. Detection of any HPV type was more common among women who were ages 18-26 (OR = 2.09, 95% CI: 1.26-3.50), current smokers (OR = 1.86, 95% CI: 1.26-2.73), had at least five male sexual partners during their lifetime (OR = 2.28, 95% CI: 1.56-3.33), or had multiple male sexual partners during the last year (OR = 1.98, 95% CI: 1.25-3.14). Similar correlates were identified for detection of a high-risk HPV type.

Conclusions: HPV was prevalent among Appalachian women, with many women having a high-risk HPV type detected. Results may help explain the high cervical cancer rates observed among Appalachian women and can help inform future cervical cancer prevention efforts in this geographic region.

Conflict of interest statement

Competing Interests: PLR, MTR, and EDP have received research grants from Merck Sharp & Dohme Corp., but none have received honoraria or consulting fees from this company. These funds were not used to support this research study. The remaining authors have no conflicts to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

References

    1. Weinstock H, Berman S, Cates W (2004) Sexually transmitted diseases among American youth: Incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 36: 6–10.
    1. Gillison ML, Chaturvedi AK, Lowy DR (2008) HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 113: 3036–3046.
    1. Lacey CJ, Lowndes CM, Shah KV (2006) Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24 Suppl 3S3/35–41.
    1. Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, et al. (2011) Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003–2006. J Infect Dis 204: 566–573.
    1. Watson M, Saraiya M, Benard V, Coughlin SS, Flowers L, et al. (2008) Burden of cervical cancer in the United States, 1998–2003. Cancer 113: 2855–2864.
    1. Appalachian Regional Commission. The Appalachian region. Available: . Last accessed 2013.
    1. Pollard K, Jacobsen LA. The Appalachian region: A data overview from the 2006–2010 American Community Survey. Available: . Last accessed 2013.
    1. Horner MJ, Altekruse SF, Zou Z, Wideroff L, Katki HA, et al. (2011) U.S. geographic distribution of prevaccine era cervical cancer screening, incidence, stage, and mortality. Cancer Epidemiol Biomarkers Prev 20: 591–599.
    1. Reiter PL, Fisher JL, Hudson AG, Tucker TC, Plascak JJ, et al. (2013) Assessing the burden of HPV-related cancers in Appalachia. Hum Vaccin Immunother 9: 90–96.
    1. Appalachia Community Cancer Network (2010) Addressing the cancer burden in Appalachian communities, 2010.
    1. Reiter PL, Katz ML, Ferketich AK, Ruffin MT, Paskett ED (2009) Measuring cervical cancer risk: Development and validation of the CARE risky sexual behavior index. Cancer Causes Control 20: 1865–1871.
    1. Kentucky Behavioral Risk Factor Surveillance System. 2008 annual report. Available: . Last accessed 2013.
    1. Giuliano AR, Sedjo RL, Roe DJ, Harri R, Baldwi S, et al. (2002) Clearance of oncogenic human papillomavirus (HPV) infection: Effect of smoking (united states). Cancer Causes Control 13: 839–846.
    1. Hall HI, Uhler RJ, Coughlin SS, Miller DS (2002) Breast and cervical cancer screening among Appalachian women. Cancer Epidemiol Biomarkers Prev 11: 137–142.
    1. Paskett ED, McLaughlin JM, Reiter PL, Lehman AM, Rhoda DA, et al. (2010) Psychosocial predictors of adherence to risk-appropriate cervical cancer screening guidelines: A cross sectional study of women in Ohio Appalachia participating in the Community Awareness Resources and Education (CARE) Project. Prev Med 50: 74–80.
    1. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, et al. (2002) The 2001 Bethesda system: Terminology for reporting results of cervical cytology. JAMA 287: 2114–2119.
    1. Ruffin MT, Hade EM, Gorsline MR, DeGraffinreid CR, Katz ML, et al. (2012) Human papillomavirus vaccine knowledge and hypothetical acceptance among women in Appalachia Ohio. Vaccine 30: 5349–5357.
    1. Onyekwuluje JM, Steinau M, Swan DC, Unger ER (2012) A real-time PCR assay for HPV52 detection and viral load quantification. Clin Lab 58: 61–66.
    1. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, et al. (2007) Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56: 1–24.
    1. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, et al. (2009) A review of human carcinogens—part B: Biological agents. Lancet Oncol 10: 321–322.
    1. International Agency for Research on Cancer (2007) Monographs on the evaluation of carcinogenic risks to humans. Volume 90: Human papillomaviruses. Lyon, France: World Health Organization, International Agency for Research on Cancer.
    1. Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, et al. (2008) Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003–2005. Ann Intern Med 148: 493–500.
    1. Dunne EF, Sternberg M, Markowitz LE, McQuillan G, Swan D, et al. (2011) Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States—National Health and Nutrition Examination Survey, 2003–2006: Opportunity to measure HPV vaccine impact? J Infect Dis 204: 562–565.
    1. Katz ML, Reiter PL, Kluhsman BC, Kennedy S, Dwyer S, et al. (2009) Human papillomavirus (HPV) vaccine availability, recommendations, cost, and policies among health departments in seven Appalachian states. Vaccine 27: 3195–3200.
    1. Christian WJ, Christian A, Hopenhayn C (2009) Acceptance of the HPV vaccine for adolescent girls: Analysis of state-added questions from the BRFSS. J Adolesc Health 44: 437–445.
    1. Katz ML, Reiter PL, Heaner S, Ruffin MT, Post DM, et al. (2009) Acceptance of the HPV vaccine among women, parents, community leaders, and healthcare providers in Ohio Appalachia. Vaccine 27: 3945–3952.
    1. Reiter PL, Katz ML, Paskett ED (2012) HPV vaccination among adolescent females from Appalachia: Implications for cervical cancer disparities. Cancer Epidemiol Biomarkers Prev 21: 2220–2230.
    1. Reiter PL, Katz ML, Paskett ED (2013) Correlates of HPV vaccination among adolescent females from Appalachia and reasons why their parents do not intend to vaccinate. Vaccine 31: 3121–3125.
    1. Centers for Disease Control and Prevention (2012) Adult vaccination coverage—United States, 2010. MMWR Morb Mortal Wkly Rep 61: 66–72.
    1. Centers for Disease Control and Prevention (2011) National and state vaccination coverage among adolescents aged 13 through 17 years — United States, 2010. MMWR Morb Mortal Wkly Rep 60: 1117–1123.
    1. Lindau ST, Drum ML, Gaumer E, Surawska H, Jordan JA (2008) Prevalence of high-risk human papillomavirus among older women. Obstet Gynecol 112: 979–989.
    1. Burchell AN, Winer RL, de Sanjose S, Franco EL (2006) Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 24 Suppl 3S52–61.
    1. Head KJ, Cohen EL (2012) Young women's perspectives on cervical cancer prevention in Appalachian Kentucky. Qual Health Res 22: 476–487.
    1. Appalachia Community Cancer Network (2009) The cancer burden in Appalachia, 2009.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe